Back to School: How biopharma can reboot drug development. Access exclusive analysis here

A bird in the hand

With its funds dwindling, Raven Biotechnologies Inc. last week looks to have pulled off the equivalent of a small IPO through its planned reverse merger with publicly traded VaxGen Inc., a company with cash but no pipeline left to call its own.

Indeed, all of the newco's development programs will come from Raven. The lead product is RAV12, a MAb against an undisclosed cell-surface antigen that is expected to begin Phase II testing to treat pancreatic and colon cancer next year. The company also has four MAbs in preclinical testing to treat various cancers. Wyeth (WYE, Madison,

Read the full 970 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers